On page 55256, in the State of California, in the County of Fresno, in the Funding to the following counties column, delete ''752,322'' and replace with ''798,213''.

On page 55256, in the State of California, in the County of Nevada, in the Funding to the following counties column, delete ''$1,077,655'' and replace with ''$1,146,292''.

On page 55256, in the State of California, in the County of San Mateo, in the Funding to the following counties column, delete ''$641,039'' and replace with ''$1,072,738'' and in the Current service area column, delete ''Half Moon Bay'' with replace with ''Entire County''.

On page 55256, in the State of Colorado, in the County of Denver, next to the Funding amount of $1,380,779, in the Current service area column, after Montbello delete ''and City Park'' and replace with ''City Park, Globeville, Skyland and North Capitol Hill''.

On page 55257, in the State of Hawaii, in the County of Oahu, in the Funding for the following counties column, delete ''$635,745'' and replace with ''$678,925'' and in the County of Oahu, in the Funding for the following counties column, delete ''$453,443'' and replace with ''$481,104''.

On page 55257, in the State of Idaho, add ''Nez Perce'' to the County Column, and add ''Nez Perce Reservation'' in the Current service area column.

On page 55259, in the State of New York, in the County of Saratoga, in the Funding for the following counties column, delete ''$998,746'' and replace with ''$927,124''.

On page 55259, in the State of North Dakota, delete ''Carson'' from the County column, delete ''$797,487'' from the Funding for the following counties column, and delete ''Boundaries of Standing Rock Reservation'' from the Current service area column.

On page 55259, in the State of North Dakota, in the County of Sioux, add ''$797,487'' to the Funding for the following counties column and delete ''Boundaries of Standing Rock Reservation'' from the Current service area column and replace with ''Standing Rock Sioux Reservation''.

On page 55259, in the State of South Dakota, in the County of Pennington, in the Funding for the following counties column, delete ''$795,140'' and replace with ''$1,155,140''.

On page 55259, in the State of South Dakota, in the County column, after Meade, add the following County: ''Lawrence'' and in the Current service area column add ''Entire County''.

On page 55259, in the State of South Dakota, in the County column after Lawrence, add the following County: ''Fall River'' and in the Current service area column add ''Entire County''.

On page 55259, in the State of South Dakota, in the County Column after ''Fall River'', add the following County: ''Custer'' and in the Current service area column add ''Entire County''.

On page 55259, in the State of South Dakota, in the County Column after ''Custer'', add the following County: ''Jackson'' and in the Current service area column add ''Entire County''.

On page 55259, in the State of South Dakota, in the County Column after ''Jackson'', add the following County: ''Haakon'' and in the Current service area column add ''Entire County''.

On page 55259, in the State of South Dakota, add ''Corson'' to the County column, and in the Current service area column add ''Standing Rock Sioux Reservation'' and add the following note in the Current service area column: ''Note: for funding level see North Dakota, Sioux County''.

On page 55260, in the State of Virginia, in the County of Buchanan, in the Funding for the following counties column, delete ''$425,640'' and replace with ''$657,534''.

FOR FURTHER INFORMATION CONTACT: The ACYF Operations Center at 1–800–351–2293 or send an email to *chs@lcgnet.com*. You can also contact Judith Jerald, Early Head Start, Head Start Bureau at (202) 205–8074.

Dated: October 24, 2000.

Patricia Montoya,

Commission, Administration on Children, Youth and Families.

[FR Doc. 00–27970 Filed 10–31–00; 8:45 am]

BILLING CODE 4184–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Request for Nominations for Members on Public Advisory Committees; Pharmacy Compounding Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for four members to serve on the Pharmacy Compounding Advisory Committee in the Center for Drug Evaluation and Research.

FDA has special interest in ensuring that women, minority groups, and the physically challenged are adequately represented on advisory committees and, therefore, extends particular encouragement to nominations for appropriately qualified female, minority, or physically challenged candidates. Final selection from among each vacancy will be determined by the expertise required to meet specific agency needs and in a manner to ensure appropriate balance of membership.

DATES: Nominations should be received on or before December 1, 2000.

ADDRESSES: All nominations for membership should be sent to Jayne E. Peterson (address below).

FOR FURTHER INFORMATION CONTACT: *Regarding all nominations for membership*: Jayne E. Peterson, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7001.

SUPPLEMENTARY INFORMATION: On November 21, 1997, the President signed the Food and Drug Administration Modernization Act of 1997 (Public Law 105–115) (the Modernization Act). Section 127 of the Modernization Act added section 503A to the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 353a)). Section 503A of the act directs FDA to issue regulations relating to the application of Federal law to the practice of pharmacy compounding. To assist the agency in preparing these regulations, Congress directed FDA to convene and consult an advisory committee that will include representatives of the National Association of Boards of Pharmacy (NABP), the United States Pharmacopeia (USP), pharmacy, physician and consumer organizations, as well as other experts selected by the agency. The Pharmacy Compounding Advisory Committee was formed on March 10, 1998, and 15 members were appointed to the committee. The terms of four members have expired or the positions have otherwise become vacant. Accordingly, FDA is requesting nominations for four members to serve on the Pharmacy Compounding Advisory Committee.

Function

The function of the committee is to provide advice on scientific, technical, and medical issues concerning drug compounding by licensed practitioners and to make appropriate recommendations to the Commissioner of Food and Drugs.

Criteria for Members

Persons nominated for membership should have expertise in one or more of the following fields: Pharmaceutical

compounding, the practices of pharmacies specializing in compounding, the practices of general retail pharmacies, the practices of hospital pharmacies, fields of medicine in which compounding drugs or the use of compounded drugs is relatively common, pharmaceutical manufacturing, clinical toxicology, clinical pharmacology, chemistry, and related specialties. The current committee includes one representative of the NABP, one representative of the USP, one representative of a consumer organization, and one representative of the pharmaceutical manufacturing industry whose terms have not yet expired. The term of office is up to 4 years.

Nomination Procedures

Interested persons may nominate one or more qualified persons for membership on the advisory committee. Nominations shall state that the nominee is willing to serve as a member of the advisory committee and appears to have no conflict of interest that would preclude committee membership. Potential candidates will be asked by FDA to provide detailed information concerning such matters as financial holdings, consultancies, and research grants or contracts to permit evaluation of possible sources of conflict of interest.

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2), section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a), section 904 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 394) as amended by the Food and Drug Administration Revitalization Act (Public Law 101–635), and 21 CFR part 14, relating to advisory committees.

Dated: October 25, 2000.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 00–27966 Filed 10–31–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This Notice is also available on the internet at the following website: *http://www.health.org/workplace.*

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, 5600 Fishers Lane, Rockwall 2 Building, Room 815, Rockville, Maryland 20857; Tel.: (301) 443–6014, Fax: (301) 443–3031.

Special Note: Please use the above address for all surface mail and correspondence. For all overnight mail service use the following address: Division of Workplace Programs, 5515 Security Lane, Room 815, Rockville, Maryland 20852.

SUPPLEMENTARY INFORMATION:

Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100–71. Subpart C of the Guidelines, ''Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies,'' sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414–328–7840/800–877–7016, (Formerly: Bayshore Clinical Laboratory).

Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901–794–5770/888–290–1150.

Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, 615–255–2400.

Alabama Reference Laboratories, Inc., 543 South Hull St., Montgomery, AL 36103, 800–541–4931/334–263–5745.

Alliance Laboratory Services, 3200 Burnet Ave., Cincinnati, OH 45229, 513–585–9000, (*Formerly:* Jewish Hospital of Cincinnati, Inc.).

American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 20151, 703–802–6900.

Associated Pathologists Laboratories, Inc., 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119–5412, 702–733–7866/800–433–2750.

Baptist Medical Center—Toxicology Laboratory, 9601 I–630, Exit 7, Little Rock, AR 72205–7299, 501–202–2783 (Formerly: Forensic Toxicology Laboratory Baptist Medical Center)

Clinical Laboratory Partners, LLC, 129 East Cedar St., Newington, CT 06111, 860–696–8115 (Formerly: Hartford Hospital Toxicology Laboratory)

Clinical Reference Lab, 8433 Quivira Rd., Lenexa, KS 66215–2802, 800–445–6917

Cox Health Systems, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, 800–876–3652/417–269–3093 (Formerly: Cox Medical Centers)

Dept. of the Navy, Navy Drug Screening Laboratory, Great Lakes, IL, Building 38–H, P.O. Box 88–6819, Great Lakes, IL 60088–6819, 847–688–2045/847–688–4171

Diagnostic Services Inc., dba DSI, 12700 Westlinks Drive, Fort Myers, FL 33913, 941–561–8200/800–735–5416

Doctors Laboratory, Inc., P.O. Box 2658, 2906 Julia Dr., Valdosta, GA 31602, 912–244–4468

DrugProof, Division of Dynacare/Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104, 206–386–2672/800–898–0180 (Formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.)

DrugScan, Inc., P.O. Box 2969, 1119 Mearns Rd., Warminster, PA 18974, 215–674–9310

Dynacare Kasper Medical Laboratories,* 14940–123 Ave., Edmonton, Alberta,